Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC June 3, 2026 8:30 AM EDT Click here for webcast Supporting Materials Interim Results from the Randomized, Controlled Phase 2 CRDF-004 Trial 1.3 MB
